Indication
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
4 clinical trials
3 products
3 drugs
Clinical trial
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck CancerStatus: Completed, Estimated PCD: 2016-10-29
Product
CetuximabProduct
IpilimumabClinical trial
Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive TreatmentStatus: Terminated, Estimated PCD: 2019-08-28
Product
Metformide/PioglitazoneClinical trial
Phase 2 Study (With Safety Lead in) of the Safety, Tolerability and Efficacy of Anti-CTLA4 (Ipilimumab) and Anti-PD-1 (Nivolumab) in Combination With Radiation Therapy to 50-66 Gy in Low-Intermediate Volume, Local-Regionally Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)Status: Recruiting, Estimated PCD: 2025-06-30
Drug
LurbinectedinDrug
T-VECClinical trial
Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window TrialStatus: Terminated, Estimated PCD: 2022-05-24
Drug
Alpelisib